MMS

Analyst Note: Maximus, Inc. (MMS)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

Current State: FORMING

• Conservative Entry: $97.05 (Breakout level)
• Current Price: $55.74
• Extension: -42.6% vs. conservative entry
• Breakout Level: $97.05
• ATR Context: The ATR at the potential breakout point was recorded at 2.4% (sub-threshold), indicating structural quality at the setup origin. Current ATR is 3.8% (productive), suggesting active volatility suitable for position sizing if the setup were to trigger.

2. Thesis Layer

Thesis Status: TACTICAL / SETUP-LED There is no named secular thesis attached to this setup as of 2026-06-13. This is not a macro-driven trade based on a specific industry-wide secular tailwind identified in the current data. The conviction must be derived entirely from the quality of the structural setup (once confirmed) and the underlying business fundamentals. We are judging this name strictly on its ability to execute its operational plan and the technical structure's readiness, without inventing a macro narrative.

3. Business Overview

Company: Maximus, Inc. (MMS) Industry: Business Process Services (BPS) for Government Health and Human Welfare. Business Model: Maximus operates as a technology-enabled services provider, translating public policy into operating models for government agencies. The company generates revenue through long-term contracts to manage program operations, clinical services, and technology solutions.

Segment Breakdown (as of FY2025/2026):

• U.S. Federal Services (56% of FY2025 revenue): Delivers solutions to federal agencies, including program operations, clinical services, and advanced technology.
• U.S. Services (32% of FY2025 revenue): Provides services to state and local governments, including Medicaid/CHIP administration, ACA marketplaces, and TANF programs.
• Outside the U.S. (11% of FY2025 revenue): Delivers BPS to international governmental bodies and commercial enterprises.

Key Operational Highlights (Source: Earnings Transcript 2026-05-07 & SEC Filings):

• Guidance: Management expects full-year adjusted EBITDA margin for FY2026 to be approximately 14.2%, a 20 basis point improvement from prior guidance. Adjusted EPS is guided to range between $8.05 and $8.55.
• Segment Margins: The U.S. Federal Services segment is anticipated to achieve an operating margin of 17.5%, while the U.S. Services segment is expected to reach 10%.
• Contract Activity: Year-to-date signed contract awards as of Q2 2026 totaled $913 million in total contract value.
• Backlog Visibility: As of March 31, 2026, remaining performance obligations were $250 million, with management anticipating revenue recognition on approximately 55% of this balance within the next 12 months.
• Cash Flow: Free cash flow is expected to range between $450 million and $500 million for FY2026.
• Regulatory Catalyst: The company is positioned to benefit from the "One Big Beautiful Bill Act" (OBBBA), signed July 4, 2025. Specifically, changes to Medicaid eligibility (more frequent redeterminations and work requirements effective Dec 31, 2026) are expected to necessitate greater management by states, driving demand for Maximus's services.

4. Archetype and Conviction

Archetype: Defensive Operator This classification fits the company's profile as a stable provider of essential government services with predictable cash flows and high barriers to entry due to regulatory complexity. The business model is defensive, as government spending on health and human services is generally inelastic.

Conviction Stack Analysis:

• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: High. The evidence base is robust, featuring specific management guidance on margins, EPS, and cash flow, alongside clear regulatory tailwinds (OBBBA).
• Structural Quality: Mixed. The ATR at the breakout point (2.4%) was sub-threshold, suggesting the setup was structurally sound but perhaps lacked the volatility to drive a rapid expansion. Current volatility (3.8%) is productive.
• Rerating Potential: Moderate. The margin expansion guidance (14.2% EBITDA) and the regulatory tailwinds from the OBBBA provide a fundamental basis for a rerating, but the technical setup requires a breakout above $97.05 to confirm this.

Valuation Context: Forward consensus EPS for FY1 is $8.435 and FY2 is $9.07. With a current price of $55.74, the stock trades at approximately 6.6x FY1 EPS. This valuation appears compressed relative to the guidance of $8.05-$8.55 EPS and the 14.2% EBITDA margin, suggesting the market may be pricing in significant execution risk or regulatory uncertainty despite the strong guidance.

5. Invalidations, Strengths, and Gaps

What Would Invalidate:

• Management guidance degradation (e.g., missing the $8.05-$8.55 EPS range or EBITDA margin below 14.2%).
• Failure to recognize the anticipated 55% of the $250M backlog within 12 months.

What Would Strengthen:

• A sustained close above $97.05 (Breakout), confirming the "Confirmed" status.
• Further upward revisions to the FY2026 EPS or EBITDA guidance.
• Confirmation that the OBBBA-driven Medicaid redeterminations are driving immediate revenue growth in the U.S. Services segment.

Evidence Gaps:

• No named secular thesis: The lack of a broader macro narrative limits the conviction stack to pure tactical execution.
• Price Action Disconnect: The significant gap between the current price ($55.74) and the breakout level ($97.05) suggests a lack of market participation or a fundamental disconnect that has not yet been resolved by price.
• Regulatory Timing: While the OBBBA is cited, the specific timing of revenue recognition from the new eligibility requirements (effective Dec 31, 2026) is a future variable not yet fully realized in the current financials.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Management guidance for 14.2% EBITDA margin and $8.05-$8.55 EPS; $913M in YTD signed contract awards; regulatory tailwinds from OBBBA Medicaid changes. Key risks: Price remains deeply extended (-42.6%) below breakout level; ATR at breakout was sub-threshold indicating weak structural momentum; regulatory implementation delays could impact backlog recognition. Sizing hint: Position size should be zero until breakout confirmation; current setup is not actionable for entry. Expected path: Management expects margin expansion and cash flow generation; structural implications suggest a potential rerating if the OBBBA-driven demand materializes as guided. Expected horizon: 12-18 months for the regulatory tailwinds to fully impact the financials.